IART

Analyst Note: IART (Integra LifeSciences Holdings Corporation)

Date: 2026-06-13 Current Price: $17.58

1. Structural Readiness

• State: Forming.
• Conservative Entry: — (Pending confirmed breakout above the coil high).
• Aggressive/Pre-Breakout Entry: — (Not actionable on setup alone; requires confirmation).
• Breakout Level: — (Pending confirmation of price closing above the coil resistance).
• Current Price: $17.58.
• Extension: — (Price is currently within the consolidation range, not extended).

2. Thesis Layer

• Thesis Status: TACTICAL / SETUP-LED.
• Macro Context: There is no named secular thesis attached to this specific setup at this date. The investment case is not driven by a broad macro theme (e.g., "aging population" or "AI in healthcare") but is strictly a function of the company's operational execution and the technical setup quality.
• Judgment Criteria: The conviction must be derived entirely from the quality of the setup (structural integrity) and the fundamental business fundamentals (margin expansion, guidance adherence) as of June 2026. No external thesis should be invented to bolster the case.

3. Business Overview

Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. The company operates through two primary business segments:

• Codman Specialty Surgical (CSS): Represents approximately 70% of total revenue. This segment provides market-leading technologies for neurosurgery, neurocritical care, and otolaryngology (ENT). Key products include dural repair solutions, cerebral spinal fluid management systems, and cranial stabilization devices.
• Tissue Technologies (TT): Represents approximately 30% of total revenue. This segment focuses on wound reconstruction and regenerative technology, including skin and wound repair, hernia repair, and nerve protection.

Operational Status as of June 2026:

• Revenue Performance: For the three months ended March 31, 2026, total revenues increased by $9.3 million to $391.9 million (up from $382.7 million in the prior year period), representing low-single-digit growth.
• Segment Growth:
• Global Neurosurgery: Delivered 1.9% organic growth, supported by demand for Certas Plus, CUSA, and BactiSeal.
• Tissue Reconstruction: Revenues reached $109 million, up 6.7% reported and 6.4% organic.
• Wound Reconstruction Franchise: Increased 6.2%, fueled by double-digit growth in Integra Skin, mid-double-digit growth in DuraSorb, and the PriMatrix launch.
• Market Exposure: Approximately 90% of Wound Reconstruction revenue is generated from the inpatient market, which management notes is not impacted by recent policy changes affecting outpatient settings.
• Restructuring: A restructuring initiative approved in Q4 2025 is ongoing, with aggregate costs of approximately $12.3 million related to severance and employee costs aimed at strengthening supply chain stability and commercial capabilities.

4. Archetype and Conviction Analysis

• Archetype: Margin Inflector.
• Rationale: The company is transitioning from a period of operational restructuring to a phase of margin expansion.
• Evidence: Gross margin expanded significantly from 50.8% in Q1 2025 to 55.4% in Q1 2026. This 460 basis point improvement aligns with the "Margin Inflector" archetype, driven by the completion of the restructuring initiative and operational efficiencies.
• Guidance: Management is maintaining 2026 revenue guidance of $1.66 billion to $1.7 billion and has updated adjusted EPS guidance to a range of $2.40 to $2.50.
• Valuation Context: The financial spine indicates a forward consensus EPS (FY1) of $2.438 and FY2 of $2.611. At a current price of $17.58, the stock trades at approximately 7.2x FY1 consensus, suggesting a valuation that reflects the turnaround narrative rather than premium growth pricing.
• Conviction Stack:
• Thesis Strength: Moderate (Tactical, no macro tailwinds).
• Evidence Quality: High (Clear guidance, specific margin expansion, segment growth data).
• Structural Quality: Moderate (Forming coil, high volatility).
• Rerating Potential: Dependent on the successful operationalization of the Braintree facility and subsequent PMA approvals.

Volatility Context:

• Current ATR: 4.8% (High). This falls within the historical "sweet spot" (4–6%) for structural setups, indicating sufficient volatility to support a move but not so extreme as to suggest a "severe loser" profile (>8%).
• ATR at Breakout: — (Not yet established).

5. Invalidation, Strengthening, and Gaps

• Strengthening: A confirmed breakout above the coil resistance level would validate the setup. Fundamentally, the successful launch of SurgiMend by year-end 2026 and the operationalization of the Braintree facility by end-June 2026 (as stated in guidance) would strengthen the case.
• Gaps in Evidence:
• PMA Approval Timing: There is a discrepancy in the timeline for PMA approvals. E2/E8 state PMA approval is anticipated in 2027, while E9/E17 (from Feb 2026) expressed hope for approval in 2026. The current status of DuraSorb PMA approval as of June 2026 is not explicitly confirmed in the latest June 12 cache, creating a timing gap.
• Breakout Level: The specific price level for the breakout is not defined in the current data stream.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Gross margin expansion from 50.8% to 55.4% in Q1 2026; Management maintaining full-year revenue guidance of $1.66B-$1.7B and raising EPS guidance to $2.40-$2.50; Braintree facility expected operational by end of June 2026. Sizing hint: Position size should be conservative given the "forming" status and high ATR; treat as a partial position awaiting confirmation. Expected path: Management executes Braintree launch and SurgiMend relaunch; price consolidates near current levels until a confirmed breakout occurs or guidance is reaffirmed in Q2 earnings. Expected horizon: 3 to 6 months for setup confirmation or invalidation.